Wockhardt gets USFDA nod for generic anti-bacterial drug
New Delhi : Drug firm Wockhardt has received approval from the US health regulator to market generic version of Wyeth's Zosyn, used for treating bacterial infections, in the American market.
The application for the product to the US Food and Drug Administration (USFDA) was made by the company's subsidiary Wockhardt Bio AG, the Mumbai-based company said in a regulatory filing.
"Wockhardt Bio AG had filed this abbreviated new drug application (ANDA) in collaboration with Fresinius Kabi, Italy (FKAI) where the product development was completed," it added.
The ANDA will be manufactured commercially at FKAI, Mitim, Italy, it said.
Wockhardt stock closed 2.54 per cent down at Rs 727.60 on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd